<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00847626</url>
  </required_header>
  <id_info>
    <org_study_id>TAK-491CLD_302</org_study_id>
    <secondary_id>2008-004218-28</secondary_id>
    <secondary_id>U1111-1113-8735</secondary_id>
    <nct_id>NCT00847626</nct_id>
    <nct_alias>NCT00892645</nct_alias>
  </id_info>
  <brief_title>Efficacy and Safety of Azilsartan Medoxomil Combined With Chlorthalidone in Participants With Moderate to Severe Hypertension</brief_title>
  <official_title>A Phase 3, Double-Blind, Randomized, Factorial, Efficacy and Safety Study of TAK 491 Plus Chlorthalidone Fixed-Dose Combination in Participants With Moderate to Severe Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy and safety of azilsartan medoxomil
      combined with chlorthalidone, once daily (QD), in participants with moderate to severe
      hypertension.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      According to the World Health Organization (WHO), hypertension is the most common
      attributable cause of preventable death in developed nations, as uncontrolled hypertension
      greatly increases the risk of cardiovascular disease, cerebrovascular disease, and renal
      failure. As the population ages, the prevalence of hypertension will continue to increase if
      broad and effective preventive measures are not implemented. Despite the availability of
      antihypertensive agents, hypertension remains inadequately controlled; only about one third
      of patients continue to maintain control successfully.

      Although most antihypertensive agents are effective at the appropriate dose, the majority
      have side effects that limit their use. As a class, angiotensin II receptor blockers
      generally are considered more tolerable than other classes of antihypertensive agents.
      TAK-491 (azilsartan medoxomil) is an angiotensin II receptor blocker that is being evaluated
      by Takeda to treat essential hypertension.

      Treatments for essential hypertension commonly include use of a thiazide-like diuretic,
      either alone or as part of combination treatment.

      This study is designed to compare the antihypertensive effect and the safety and tolerability
      of the azilsartan medoxomil plus chlorthalidone fixed-dose combination product (TAK 491CLD
      FDC) with azilsartan monotherapy and chlorthalidone monotherapy during 8 weeks of treatment.

      Participants in this study will be randomized to receive one of 11 possible dosing
      combinations of azilsartan medoxomil , chlorthalidone and placebo over an 8 week period. The
      total duration of the study will be approximately 13 weeks. Participants will make 12 visits
      to the clinic. Each participant will also be contacted by telephone 14 days after last dose
      of study drug for a follow-up assessment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline to Week 8 in Trough, Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring (Pooled Analysis)</measure>
    <time_frame>Baseline and Week 8.</time_frame>
    <description>The change in trough systolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough is the average of all measurements recorded from 22 to 24 hours after dosing.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline to Week 8 in Trough, Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring (Pairwise Analysis)</measure>
    <time_frame>Baseline and Week 8.</time_frame>
    <description>The change in trough systolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough is the average of all measurements recorded from 22 to 24 hours after dosing.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 8 in Trough, Sitting, Clinic Systolic Blood Pressure</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>The change in trough systolic blood pressure measured at final visit or week 8 relative to baseline. Systolic blood pressure is the arithmetic mean of the 3 serial trough sitting systolic blood pressure measurements.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 8 in Trough Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring in Black Participants (Pooled Analysis)</measure>
    <time_frame>Baseline and Week 8.</time_frame>
    <description>The change in trough systolic blood pressure in black subjects measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough is the average of all measurements recorded from 22 to 24 hours after dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 8 in Trough Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring in Black Participants (Pairwise Analysis)</measure>
    <time_frame>Baseline and Week 8.</time_frame>
    <description>The change in trough systolic blood pressure in black participants as measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough is the average of all measurements recorded from 22 to 24 hours after dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 8 in Trough, Sitting, Clinic Diastolic Blood Pressure</measure>
    <time_frame>Baseline and Week 8.</time_frame>
    <description>The change in trough diastolic blood pressure measured at final visit or week 8 relative to baseline. Diastolic blood pressure is the average of the 3 serial trough clinic sitting diastolic blood pressure measurements.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 8 in the Mean Trough Diastolic Blood Pressure (22 to 24 Hours After Dosing), as Measured by Ambulatory Blood Pressure Monitoring.</measure>
    <time_frame>Baseline and Week 8.</time_frame>
    <description>The change in trough diastolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough is the average of all measurements recorded from 22 to 24 hours after dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 8 in the 24-hour Mean Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring</measure>
    <time_frame>Baseline and Week 8.</time_frame>
    <description>The change in 24-hour mean systolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 8 in the 24-hour Mean Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring</measure>
    <time_frame>Baseline and Week 8.</time_frame>
    <description>The change in 24-hour mean diastolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 8 in the Mean Daytime (6 AM to 10 PM) Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring.</measure>
    <time_frame>Baseline and Week 8.</time_frame>
    <description>The change in daytime (6am to 10pm) mean systolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 8 in the Mean Daytime (6 AM to 10 PM) Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring.</measure>
    <time_frame>Baseline and Week 8.</time_frame>
    <description>The change in daytime (6am to 10pm) mean diastolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 8 in the Mean Nighttime (12 AM to 6 AM) Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring.</measure>
    <time_frame>Baseline and Week 8.</time_frame>
    <description>The change in nighttime (12am to 6am) mean systolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 8 in the Mean Nighttime (12 AM to 6 AM) Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring.</measure>
    <time_frame>Baseline and Week 8.</time_frame>
    <description>The change in nighttime (12am to 6am) mean diastolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 8 in the Mean Systolic Blood Pressure at 0 to 12 Hours After Dosing, as Measured by Ambulatory Blood Pressure Monitoring.</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>The change in the 12-hour mean systolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 8 in the Mean Diastolic Blood Pressure at 0 to 12 Hours After Dosing, as Measured by Ambulatory Blood Pressure Monitoring.</measure>
    <time_frame>Baseline and Week 8.</time_frame>
    <description>The change in the 12-hour mean diastolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieve a Clinic Systolic Blood Pressure Response at Week 8, as Defined by Clinic Systolic Blood Pressure &lt;140 mm Hg and/or a Reduction of ≥20 mm Hg From Baseline.</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>Percentage of participants who achieve a clinic systolic blood pressure response measured at week 8, defined as less than 140 mm Hg and/or reduction from baseline of greater than or equal to 20 mm Hg. Systolic blood pressure is the average of the 3 serial trough sitting clinic systolic blood pressure measurements.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieve a Clinic Diastolic Blood Pressure Response at Week 8, Defined as Clinic Diastolic Blood Pressure &lt;90 mm Hg and/or a Reduction of ≥10 mm Hg From Baseline.</measure>
    <time_frame>Baseline and Week 8.</time_frame>
    <description>Percentage of participants who achieve a clinic diastolic blood pressure response measured at week 8, defined as less than 90 mm Hg and/or reduction from baseline of greater than or equal to 10 mm Hg. Diastolic blood pressure is the average of the 3 serial trough sitting clinic diastolic blood pressure measurements.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieve Both a Clinic Systolic and Diastolic Blood Pressure Response at Week 8.</measure>
    <time_frame>Baseline and Week 8.</time_frame>
    <description>Percentage of participants who achieve both a clinic systolic and diastolic blood pressure response measured at week 8, defined as systolic blood pressure less than 140 mm Hg and/or reduction from baseline of greater than or equal to 20 mm Hg AND diastolic blood pressure less than 90 mm Hg and/or reduction from baseline of greater than or equal to 10 mm Hg . Systolic/diastolic blood pressure is based on the average of the 3 serial trough clinic sitting systolic/diastolic blood pressure measurements.</description>
  </secondary_outcome>
  <number_of_arms>11</number_of_arms>
  <enrollment type="Actual">1711</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Azilsartan medoxomil 20 mg/chlorthalidone 12.5 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Azilsartan medoxomil 20 mg/chlorthalidone 25 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Azilsartan medoxomil 40 mg/chlorthalidone 12.5 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Azilsartan medoxomil 40 mg/chlorthalidone 25 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Azilsartan medoxomil 80 mg/chlorthalidone 12.5 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Azilsartan medoxomil 80 mg/chlorthalidone 25 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Chlorthalidone 12.5 mg QD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Chlorthalidone 25 mg QD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Azilsartan medoxomil 20 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Azilsartan medoxomil 40 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Azilsartan medoxomil 80 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azilsartan medoxomil and chlorthalidone</intervention_name>
    <description>Azilsartan medoxomil 20 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks</description>
    <arm_group_label>Azilsartan medoxomil 20 mg/chlorthalidone 12.5 mg QD</arm_group_label>
    <other_name>TAK-491CLD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azilsartan medoxomil and chlorthalidone</intervention_name>
    <description>Azilsartan medoxomil 20 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks</description>
    <arm_group_label>Azilsartan medoxomil 20 mg/chlorthalidone 25 mg QD</arm_group_label>
    <other_name>TAK-491CLD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azilsartan medoxomil and chlorthalidone</intervention_name>
    <description>Azilsartan 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks</description>
    <arm_group_label>Azilsartan medoxomil 40 mg/chlorthalidone 12.5 mg QD</arm_group_label>
    <other_name>TAK-491CLD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azilsartan medoxomil and chlorthalidone</intervention_name>
    <description>Azilsartan medoxomil 40 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks</description>
    <arm_group_label>Azilsartan medoxomil 40 mg/chlorthalidone 25 mg QD</arm_group_label>
    <other_name>TAK-491CLD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azilsartan medoxomil and chlorthalidone</intervention_name>
    <description>Azilsartan 80 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks</description>
    <arm_group_label>Azilsartan medoxomil 80 mg/chlorthalidone 12.5 mg QD</arm_group_label>
    <other_name>TAK-491CLD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azilsartan medoxomil and chlorthalidone</intervention_name>
    <description>Azilsartan medoxomil 80 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks</description>
    <arm_group_label>Azilsartan medoxomil 80 mg/chlorthalidone 25 mg QD</arm_group_label>
    <other_name>TAK-491CLD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chlorthalidone</intervention_name>
    <description>Azilsartan medoxomil placebo and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks</description>
    <arm_group_label>Chlorthalidone 12.5 mg QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chlorthalidone</intervention_name>
    <description>Azilsartan medoxomil placebo and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks</description>
    <arm_group_label>Chlorthalidone 25 mg QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azilsartan medoxomil</intervention_name>
    <description>Azilsartan medoxomil 20 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks</description>
    <arm_group_label>Azilsartan medoxomil 20 mg QD</arm_group_label>
    <other_name>TAK-491CLD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azilsartan medoxomil</intervention_name>
    <description>Azilsartan medoxomil 40 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks</description>
    <arm_group_label>Azilsartan medoxomil 40 mg QD</arm_group_label>
    <other_name>TAK-491CLD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azilsartan medoxomil</intervention_name>
    <description>Azilsartan medoxomil 80 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks</description>
    <arm_group_label>Azilsartan medoxomil 80 mg QD</arm_group_label>
    <other_name>TAK-491CLD</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Is treated with antihypertensive therapy and has a post-washout mean sitting clinic
             systolic blood pressure greater than or equal to 160 and less than or equal to 190 mm
             Hg on the day prior to randomization, or the participant has not received
             antihypertensive treatment within 28 days prior to Screening and has a mean sitting
             clinic systolic blood pressure greater than or equal to 160 and less than or equal to
             190 mm Hg at the Screening Visit and on the day prior to randomization.

          2. Females of childbearing potential who are sexually active must agree to use adequate
             contraception, and can neither be pregnant nor lactating from Screening throughout the
             duration of the study.

          3. Has clinical laboratory test results within the reference range for the testing
             laboratory or the investigator does not consider the results to be clinically
             significant.

          4. Is willing to discontinue current antihypertensive medications on Day -21 or on Day
             -28 if on amlodipine or chlorthalidone.

        Exclusion Criteria:

          1. Has a mean sitting clinic diastolic blood pressure greater than 119 mm Hg on the day
             prior to randomization.

          2. Has a baseline 24-hour ambulatory blood pressure measurement reading of insufficient
             quality.

          3. Has works a night (third) shift (defined as 11 PM [2300] to 7 AM [0700]).

          4. Has an upper arm circumference less than 24 cm or greater than 42 cm.

          5. Has is noncompliant with study medication during the placebo run-in period.

          6. Has secondary hypertension of any etiology.

          7. Has recent history of myocardial infarction, heart failure, unstable angina, coronary
             artery bypass graft, percutaneous coronary intervention, hypertensive encephalopathy,
             cerebrovascular accident, or transient ischemic attack.

          8. Has clinically significant cardiac conduction defects.

          9. Has hemodynamically significant left ventricular outflow obstruction due to aortic
             valvular disease.

         10. Has severe renal dysfunction or disease.

         11. Has known or suspected unilateral or bilateral renal artery stenosis.

         12. Has a history of cancer that has not been in remission for at least 5 years prior to
             the first dose of study drug.

         13. Has poorly controlled type 1 or type 2 diabetes mellitus at Screening.

         14. Has hypokalemia or hyperkalemia.

         15. Has an alanine aminotransferase or aspartate aminotransferase level of greater than
             2.5 times the upper limit of normal, active liver disease, or jaundice.

         16. Has any other known serious disease or condition that would compromise safety, might
             affect life expectancy, or make it difficult to successfully manage and follow Has
             according to the protocol.

         17. Has known hypersensitivity to angiotensin II receptor blockers, thiazide-type
             diuretics or other sulfonamide-derived compounds.

         18. Has been randomized in a previous azilsartan medoxomil study.

         19. Is currently participating in another investigational study or is receiving or has
             received any investigational compound within 30 days prior to Screening.

         20. Has a history of drug abuse or a history of alcohol abuse within the past 2 years.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Executive Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbiana</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tuscaloosa</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Buena Park</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Carmichael</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Costa Mesa</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Palm Springs</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vista</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Middletown</city>
        <state>Delaware</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Deerfield Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hallandale Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Longwood</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ormond Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St Petersburg</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Buffalo Grove</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Libertyville</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Melrose Park</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fishers</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Erlanger</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madisonville</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paducah</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chesterfield</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brick</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Margate</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Endwell</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cary</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lyndhurst</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Willoughby Hills</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ashland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Altoona</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bensalem</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Feasterville</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jenkintown</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sellersville</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warminster</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Florence</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Murrells Inlet</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Simpsonville</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clarksville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Tazewell</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bellaire</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>McKinney</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Richardson</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Magna</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Arlington</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oregon</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Temuco</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aguascalientes</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Merida</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mexico DF</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bellavista</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chiclayo</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jesus Maria</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miraflores</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Borja</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Martin de Porres</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Trujillo</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Umacollo</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Chile</country>
    <country>Mexico</country>
    <country>Peru</country>
    <country>Russian Federation</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 18, 2009</study_first_submitted>
  <study_first_submitted_qc>February 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2009</study_first_posted>
  <results_first_submitted>January 4, 2012</results_first_submitted>
  <results_first_submitted_qc>January 4, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 7, 2012</results_first_posted>
  <last_update_submitted>January 4, 2012</last_update_submitted>
  <last_update_submitted_qc>January 4, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 7, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypertensive</keyword>
  <keyword>Blood Pressure, High</keyword>
  <keyword>Vascular Disease</keyword>
  <keyword>Cardiovascular Disease</keyword>
  <keyword>Drug Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chlorthalidone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants enrolled at 175 investigative sites in Austria, Chile, Germany, Guatemala, Mexico, Netherlands, Peru, Poland, Russian Federation and the United States from 29 January 2009 to 10 July 2010.</recruitment_details>
      <pre_assignment_details>Participants with moderate to severe essential hypertension were enrolled in one of 11, once-daily (QD) treatment groups.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Azilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QD</title>
          <description>Azilsartan medoxomil 20 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Azilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QD</title>
          <description>Azilsartan medoxomil 20 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD</title>
          <description>Azilsartan 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks.</description>
        </group>
        <group group_id="P4">
          <title>Azilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QD</title>
          <description>Azilsartan medoxomil 40 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.</description>
        </group>
        <group group_id="P5">
          <title>Azilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QD</title>
          <description>Azilsartan 80 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks.</description>
        </group>
        <group group_id="P6">
          <title>Azilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QD</title>
          <description>Azilsartan medoxomil 80 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.</description>
        </group>
        <group group_id="P7">
          <title>Chlorthalidone 12.5 mg QD</title>
          <description>Azilsartan medoxomil placebo and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks.</description>
        </group>
        <group group_id="P8">
          <title>Chlorthalidone 25 mg QD</title>
          <description>Azilsartan medoxomil placebo and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.</description>
        </group>
        <group group_id="P9">
          <title>Azilsartan Medoxomil 20 mg QD</title>
          <description>Azilsartan medoxomil 20 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks.</description>
        </group>
        <group group_id="P10">
          <title>Azilsartan Medoxomil 40 mg QD</title>
          <description>Azilsartan medoxomil 40 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks.</description>
        </group>
        <group group_id="P11">
          <title>Azilsartan Medoxomil 80 mg QD</title>
          <description>Azilsartan medoxomil 80 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="156"/>
                <participants group_id="P2" count="154"/>
                <participants group_id="P3" count="147">Includes participant who was randomized but did not receive study medication.</participants>
                <participants group_id="P4" count="156"/>
                <participants group_id="P5" count="153"/>
                <participants group_id="P6" count="162">Includes participant who was randomized but did not receive study medication.</participants>
                <participants group_id="P7" count="157">Includes participant who was randomized but did not receive study medication.</participants>
                <participants group_id="P8" count="160">Includes participant who was treated with double-blind study medication but not randomized.</participants>
                <participants group_id="P9" count="155"/>
                <participants group_id="P10" count="153"/>
                <participants group_id="P11" count="162"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="135"/>
                <participants group_id="P2" count="131"/>
                <participants group_id="P3" count="131"/>
                <participants group_id="P4" count="125"/>
                <participants group_id="P5" count="125"/>
                <participants group_id="P6" count="125"/>
                <participants group_id="P7" count="135"/>
                <participants group_id="P8" count="141"/>
                <participants group_id="P9" count="141"/>
                <participants group_id="P10" count="139"/>
                <participants group_id="P11" count="142"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="31"/>
                <participants group_id="P5" count="28"/>
                <participants group_id="P6" count="37"/>
                <participants group_id="P7" count="22"/>
                <participants group_id="P8" count="19"/>
                <participants group_id="P9" count="14"/>
                <participants group_id="P10" count="14"/>
                <participants group_id="P11" count="20"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="19"/>
                <participants group_id="P5" count="11"/>
                <participants group_id="P6" count="22"/>
                <participants group_id="P7" count="4"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="3"/>
                <participants group_id="P10" count="6"/>
                <participants group_id="P11" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="12"/>
                <participants group_id="P6" count="9"/>
                <participants group_id="P7" count="8"/>
                <participants group_id="P8" count="4"/>
                <participants group_id="P9" count="4"/>
                <participants group_id="P10" count="5"/>
                <participants group_id="P11" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="5"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Azilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QD</title>
          <description>Azilsartan medoxomil 20 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Azilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QD</title>
          <description>Azilsartan medoxomil 20 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD</title>
          <description>Azilsartan 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Azilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QD</title>
          <description>Azilsartan medoxomil 40 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.</description>
        </group>
        <group group_id="B5">
          <title>Azilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QD</title>
          <description>Azilsartan 80 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks.</description>
        </group>
        <group group_id="B6">
          <title>Azilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QD</title>
          <description>Azilsartan medoxomil 80 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.</description>
        </group>
        <group group_id="B7">
          <title>Chlorthalidone 12.5 mg QD</title>
          <description>Azilsartan medoxomil placebo and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks.</description>
        </group>
        <group group_id="B8">
          <title>Chlorthalidone 25 mg QD</title>
          <description>Azilsartan medoxomil placebo and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.</description>
        </group>
        <group group_id="B9">
          <title>Azilsartan Medoxomil 20 mg QD</title>
          <description>Azilsartan medoxomil 20 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks.</description>
        </group>
        <group group_id="B10">
          <title>Azilsartan Medoxomil 40 mg QD</title>
          <description>Azilsartan medoxomil 40 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks.</description>
        </group>
        <group group_id="B11">
          <title>Azilsartan Medoxomil 80 mg QD</title>
          <description>Azilsartan medoxomil 80 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks.</description>
        </group>
        <group group_id="B12">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="156"/>
            <count group_id="B2" value="154"/>
            <count group_id="B3" value="147"/>
            <count group_id="B4" value="156"/>
            <count group_id="B5" value="153"/>
            <count group_id="B6" value="162"/>
            <count group_id="B7" value="157"/>
            <count group_id="B8" value="159"/>
            <count group_id="B9" value="155"/>
            <count group_id="B10" value="153"/>
            <count group_id="B11" value="162"/>
            <count group_id="B12" value="1714"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.2" spread="10.57"/>
                    <measurement group_id="B2" value="57.4" spread="11.13"/>
                    <measurement group_id="B3" value="56.2" spread="10.50"/>
                    <measurement group_id="B4" value="57.4" spread="11.07"/>
                    <measurement group_id="B5" value="55.8" spread="11.22"/>
                    <measurement group_id="B6" value="57.6" spread="11.04"/>
                    <measurement group_id="B7" value="57.3" spread="11.30"/>
                    <measurement group_id="B8" value="56.2" spread="10.04"/>
                    <measurement group_id="B9" value="57.3" spread="11.04"/>
                    <measurement group_id="B10" value="57.8" spread="10.28"/>
                    <measurement group_id="B11" value="57.3" spread="10.87"/>
                    <measurement group_id="B12" value="57.2" spread="10.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;45 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="25"/>
                    <measurement group_id="B6" value="19"/>
                    <measurement group_id="B7" value="21"/>
                    <measurement group_id="B8" value="18"/>
                    <measurement group_id="B9" value="18"/>
                    <measurement group_id="B10" value="17"/>
                    <measurement group_id="B11" value="16"/>
                    <measurement group_id="B12" value="203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 45 to 64 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="98"/>
                    <measurement group_id="B2" value="97"/>
                    <measurement group_id="B3" value="100"/>
                    <measurement group_id="B4" value="93"/>
                    <measurement group_id="B5" value="90"/>
                    <measurement group_id="B6" value="104"/>
                    <measurement group_id="B7" value="97"/>
                    <measurement group_id="B8" value="108"/>
                    <measurement group_id="B9" value="97"/>
                    <measurement group_id="B10" value="98"/>
                    <measurement group_id="B11" value="107"/>
                    <measurement group_id="B12" value="1089"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="42"/>
                    <measurement group_id="B5" value="38"/>
                    <measurement group_id="B6" value="39"/>
                    <measurement group_id="B7" value="39"/>
                    <measurement group_id="B8" value="33"/>
                    <measurement group_id="B9" value="40"/>
                    <measurement group_id="B10" value="38"/>
                    <measurement group_id="B11" value="39"/>
                    <measurement group_id="B12" value="422"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="86"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="76"/>
                    <measurement group_id="B4" value="85"/>
                    <measurement group_id="B5" value="82"/>
                    <measurement group_id="B6" value="100"/>
                    <measurement group_id="B7" value="74"/>
                    <measurement group_id="B8" value="90"/>
                    <measurement group_id="B9" value="87"/>
                    <measurement group_id="B10" value="68"/>
                    <measurement group_id="B11" value="84"/>
                    <measurement group_id="B12" value="909"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="71"/>
                    <measurement group_id="B4" value="71"/>
                    <measurement group_id="B5" value="71"/>
                    <measurement group_id="B6" value="62"/>
                    <measurement group_id="B7" value="83"/>
                    <measurement group_id="B8" value="69"/>
                    <measurement group_id="B9" value="68"/>
                    <measurement group_id="B10" value="85"/>
                    <measurement group_id="B11" value="78"/>
                    <measurement group_id="B12" value="805"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="19"/>
                    <measurement group_id="B6" value="15"/>
                    <measurement group_id="B7" value="17"/>
                    <measurement group_id="B8" value="19"/>
                    <measurement group_id="B9" value="20"/>
                    <measurement group_id="B10" value="17"/>
                    <measurement group_id="B11" value="15"/>
                    <measurement group_id="B12" value="177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="76"/>
                    <measurement group_id="B4" value="85"/>
                    <measurement group_id="B5" value="71"/>
                    <measurement group_id="B6" value="87"/>
                    <measurement group_id="B7" value="84"/>
                    <measurement group_id="B8" value="86"/>
                    <measurement group_id="B9" value="77"/>
                    <measurement group_id="B10" value="80"/>
                    <measurement group_id="B11" value="86"/>
                    <measurement group_id="B12" value="897"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="60"/>
                    <measurement group_id="B4" value="56"/>
                    <measurement group_id="B5" value="63"/>
                    <measurement group_id="B6" value="60"/>
                    <measurement group_id="B7" value="56"/>
                    <measurement group_id="B8" value="54"/>
                    <measurement group_id="B9" value="58"/>
                    <measurement group_id="B10" value="56"/>
                    <measurement group_id="B11" value="61"/>
                    <measurement group_id="B12" value="640"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="16"/>
                    <measurement group_id="B7" value="14"/>
                    <measurement group_id="B8" value="14"/>
                    <measurement group_id="B9" value="11"/>
                    <measurement group_id="B10" value="13"/>
                    <measurement group_id="B11" value="14"/>
                    <measurement group_id="B12" value="142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="7"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="4"/>
                    <measurement group_id="B12" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="30"/>
                    <measurement group_id="B5" value="26"/>
                    <measurement group_id="B6" value="34"/>
                    <measurement group_id="B7" value="31"/>
                    <measurement group_id="B8" value="29"/>
                    <measurement group_id="B9" value="31"/>
                    <measurement group_id="B10" value="35"/>
                    <measurement group_id="B11" value="35"/>
                    <measurement group_id="B12" value="342"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="111"/>
                    <measurement group_id="B2" value="112"/>
                    <measurement group_id="B3" value="102"/>
                    <measurement group_id="B4" value="111"/>
                    <measurement group_id="B5" value="114"/>
                    <measurement group_id="B6" value="109"/>
                    <measurement group_id="B7" value="111"/>
                    <measurement group_id="B8" value="111"/>
                    <measurement group_id="B9" value="113"/>
                    <measurement group_id="B10" value="105"/>
                    <measurement group_id="B11" value="111"/>
                    <measurement group_id="B12" value="1210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="2"/>
                    <measurement group_id="B12" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="3"/>
                    <measurement group_id="B11" value="2"/>
                    <measurement group_id="B12" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B8" value="5"/>
                    <measurement group_id="B9" value="3"/>
                    <measurement group_id="B10" value="4"/>
                    <measurement group_id="B11" value="5"/>
                    <measurement group_id="B12" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Guatemala</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="8"/>
                    <measurement group_id="B8" value="9"/>
                    <measurement group_id="B9" value="8"/>
                    <measurement group_id="B10" value="9"/>
                    <measurement group_id="B11" value="9"/>
                    <measurement group_id="B12" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mexico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="11"/>
                    <measurement group_id="B7" value="11"/>
                    <measurement group_id="B8" value="8"/>
                    <measurement group_id="B9" value="13"/>
                    <measurement group_id="B10" value="11"/>
                    <measurement group_id="B11" value="12"/>
                    <measurement group_id="B12" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="6"/>
                    <measurement group_id="B10" value="6"/>
                    <measurement group_id="B11" value="7"/>
                    <measurement group_id="B12" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peru</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="14"/>
                    <measurement group_id="B7" value="12"/>
                    <measurement group_id="B8" value="11"/>
                    <measurement group_id="B9" value="13"/>
                    <measurement group_id="B10" value="12"/>
                    <measurement group_id="B11" value="12"/>
                    <measurement group_id="B12" value="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="7"/>
                    <measurement group_id="B8" value="8"/>
                    <measurement group_id="B9" value="8"/>
                    <measurement group_id="B10" value="7"/>
                    <measurement group_id="B11" value="8"/>
                    <measurement group_id="B12" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russian Federation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="5"/>
                    <measurement group_id="B10" value="4"/>
                    <measurement group_id="B11" value="6"/>
                    <measurement group_id="B12" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="94"/>
                    <measurement group_id="B3" value="87"/>
                    <measurement group_id="B4" value="100"/>
                    <measurement group_id="B5" value="90"/>
                    <measurement group_id="B6" value="102"/>
                    <measurement group_id="B7" value="101"/>
                    <measurement group_id="B8" value="105"/>
                    <measurement group_id="B9" value="97"/>
                    <measurement group_id="B10" value="97"/>
                    <measurement group_id="B11" value="101"/>
                    <measurement group_id="B12" value="1074"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="166.3" spread="11.71"/>
                    <measurement group_id="B2" value="166.6" spread="10.85"/>
                    <measurement group_id="B3" value="167.1" spread="11.44"/>
                    <measurement group_id="B4" value="166.8" spread="11.64"/>
                    <measurement group_id="B5" value="166.6" spread="10.81"/>
                    <measurement group_id="B6" value="165.4" spread="10.79"/>
                    <measurement group_id="B7" value="168.3" spread="11.07"/>
                    <measurement group_id="B8" value="166.1" spread="11.36"/>
                    <measurement group_id="B9" value="166.4" spread="10.65"/>
                    <measurement group_id="B10" value="167.7" spread="12.27"/>
                    <measurement group_id="B11" value="167.1" spread="11.85"/>
                    <measurement group_id="B12" value="166.8" spread="11.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="89.85" spread="22.076"/>
                    <measurement group_id="B2" value="86.06" spread="18.056"/>
                    <measurement group_id="B3" value="89.28" spread="21.484"/>
                    <measurement group_id="B4" value="90.16" spread="21.949"/>
                    <measurement group_id="B5" value="87.31" spread="19.209"/>
                    <measurement group_id="B6" value="86.44" spread="20.412"/>
                    <measurement group_id="B7" value="89.12" spread="21.049"/>
                    <measurement group_id="B8" value="86.70" spread="20.270"/>
                    <measurement group_id="B9" value="87.27" spread="18.934"/>
                    <measurement group_id="B10" value="87.54" spread="19.019"/>
                    <measurement group_id="B11" value="86.27" spread="20.354"/>
                    <measurement group_id="B12" value="87.80" spread="20.289"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.2" spread="5.73"/>
                    <measurement group_id="B2" value="31.0" spread="5.65"/>
                    <measurement group_id="B3" value="31.8" spread="6.57"/>
                    <measurement group_id="B4" value="32.2" spread="6.01"/>
                    <measurement group_id="B5" value="31.4" spread="5.84"/>
                    <measurement group_id="B6" value="31.5" spread="6.28"/>
                    <measurement group_id="B7" value="31.2" spread="5.85"/>
                    <measurement group_id="B8" value="31.2" spread="5.78"/>
                    <measurement group_id="B9" value="31.3" spread="5.23"/>
                    <measurement group_id="B10" value="31.0" spread="5.85"/>
                    <measurement group_id="B11" value="30.8" spread="6.28"/>
                    <measurement group_id="B12" value="31.4" spread="5.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking Status</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Never smoked</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="94"/>
                    <measurement group_id="B2" value="84"/>
                    <measurement group_id="B3" value="81"/>
                    <measurement group_id="B4" value="79"/>
                    <measurement group_id="B5" value="91"/>
                    <measurement group_id="B6" value="94"/>
                    <measurement group_id="B7" value="93"/>
                    <measurement group_id="B8" value="91"/>
                    <measurement group_id="B9" value="92"/>
                    <measurement group_id="B10" value="90"/>
                    <measurement group_id="B11" value="94"/>
                    <measurement group_id="B12" value="983"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Current smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="35"/>
                    <measurement group_id="B5" value="26"/>
                    <measurement group_id="B6" value="28"/>
                    <measurement group_id="B7" value="25"/>
                    <measurement group_id="B8" value="29"/>
                    <measurement group_id="B9" value="25"/>
                    <measurement group_id="B10" value="31"/>
                    <measurement group_id="B11" value="29"/>
                    <measurement group_id="B12" value="303"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ex-smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="41"/>
                    <measurement group_id="B4" value="42"/>
                    <measurement group_id="B5" value="36"/>
                    <measurement group_id="B6" value="40"/>
                    <measurement group_id="B7" value="39"/>
                    <measurement group_id="B8" value="39"/>
                    <measurement group_id="B9" value="38"/>
                    <measurement group_id="B10" value="32"/>
                    <measurement group_id="B11" value="39"/>
                    <measurement group_id="B12" value="428"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Estimated glomerular filtration rate (eGFR)</title>
          <description>eGFR based on calculated creatinine clearance.
Categories:
Normal renal function (≥90 mL/min/1.73 m2) Mild renal impairment(60 to &lt;90 mL/min/1.73 m2) Moderate renal impairment (30 to &lt;60 mL/min/1.73 m2) Severe renal impairment (0 to &lt;30 mL/min/1.73 m2)
Includes all randomized participants</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>≥0 and &lt;30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥30 and &lt;60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="10"/>
                    <measurement group_id="B7" value="12"/>
                    <measurement group_id="B8" value="9"/>
                    <measurement group_id="B9" value="11"/>
                    <measurement group_id="B10" value="11"/>
                    <measurement group_id="B11" value="8"/>
                    <measurement group_id="B12" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥60 and &lt;90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="95"/>
                    <measurement group_id="B2" value="90"/>
                    <measurement group_id="B3" value="93"/>
                    <measurement group_id="B4" value="97"/>
                    <measurement group_id="B5" value="109"/>
                    <measurement group_id="B6" value="110"/>
                    <measurement group_id="B7" value="101"/>
                    <measurement group_id="B8" value="100"/>
                    <measurement group_id="B9" value="94"/>
                    <measurement group_id="B10" value="95"/>
                    <measurement group_id="B11" value="99"/>
                    <measurement group_id="B12" value="1083"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="48"/>
                    <measurement group_id="B4" value="51"/>
                    <measurement group_id="B5" value="38"/>
                    <measurement group_id="B6" value="42"/>
                    <measurement group_id="B7" value="44"/>
                    <measurement group_id="B8" value="50"/>
                    <measurement group_id="B9" value="49"/>
                    <measurement group_id="B10" value="46"/>
                    <measurement group_id="B11" value="55"/>
                    <measurement group_id="B12" value="521"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to Week 8 in Trough, Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring (Pooled Analysis)</title>
        <description>The change in trough systolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough is the average of all measurements recorded from 22 to 24 hours after dosing.</description>
        <time_frame>Baseline and Week 8.</time_frame>
        <population>Full analysis set, defined as all randomized participants who received at least 1 dose of double-blind study medication, with both a baseline value and at least 1 post-baseline value, with last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Azilsartan Medoxomil 40 mg or 80 mg/Chlorthalidone 25 mg QD</title>
            <description>Azilsartan medoxomil 40 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.
OR
Azilsartan medoxomil 80 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Chlorthalidone 25 mg QD</title>
            <description>Azilsartan medoxomil placebo and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Azilsartan Medoxomil 80 mg QD</title>
            <description>Azilsartan medoxomil 80 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 8 in Trough, Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring (Pooled Analysis)</title>
          <description>The change in trough systolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough is the average of all measurements recorded from 22 to 24 hours after dosing.</description>
          <population>Full analysis set, defined as all randomized participants who received at least 1 dose of double-blind study medication, with both a baseline value and at least 1 post-baseline value, with last observation carried forward.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="228"/>
                <count group_id="O2" value="134"/>
                <count group_id="O3" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.9" spread="0.89"/>
                    <measurement group_id="O2" value="-15.9" spread="1.16"/>
                    <measurement group_id="O3" value="-15.1" spread="1.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis of covariance model (ANCOVA) using treatment as a fixed effect and baseline as a covariate was performed. Results for Azilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QD and Azilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QD pool were obtained using contrast with coefficients of 0.5 for Azilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QD and 0.5 for Azilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QD from the ANCOVA model.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Tested at 5% significance level.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-13.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.8</ci_lower_limit>
            <ci_upper_limit>-9.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>ANCOVA using treatment as a fixed effect and baseline as a covariate was performed. Results for Azilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QD and Azilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QD pool were obtained using contrast with coefficients of 0.5 for Azilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QD and 0.5 for Azilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QD from the ANCOVA model.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Tested at 5% significance level.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-13.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.7</ci_lower_limit>
            <ci_upper_limit>-10.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 8 in Trough, Sitting, Clinic Systolic Blood Pressure</title>
        <description>The change in trough systolic blood pressure measured at final visit or week 8 relative to baseline. Systolic blood pressure is the arithmetic mean of the 3 serial trough sitting systolic blood pressure measurements.</description>
        <time_frame>Baseline and Week 8</time_frame>
        <population>Full analysis set, defined as all randomized participants who received at least 1 dose of double-blind study medication, with both a baseline value and at least 1 post-baseline value, with last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Azilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QD</title>
            <description>Azilsartan medoxomil 20 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Azilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QD</title>
            <description>Azilsartan medoxomil 20 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD</title>
            <description>Azilsartan 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Azilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QD</title>
            <description>Azilsartan medoxomil 40 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Azilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QD</title>
            <description>Azilsartan 80 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Azilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QD</title>
            <description>Azilsartan medoxomil 80 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Chlorthalidone 12.5 mg QD</title>
            <description>Azilsartan medoxomil placebo and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Chlorthalidone 25 mg QD</title>
            <description>Azilsartan medoxomil placebo and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O9">
            <title>Azilsartan Medoxomil 20 mg QD</title>
            <description>Azilsartan medoxomil 20 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O10">
            <title>Azilsartan Medoxomil 40 mg QD</title>
            <description>Azilsartan medoxomil 40 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Azilsartan Medoxomil 80 mg QD</title>
            <description>Azilsartan medoxomil 80 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 8 in Trough, Sitting, Clinic Systolic Blood Pressure</title>
          <description>The change in trough systolic blood pressure measured at final visit or week 8 relative to baseline. Systolic blood pressure is the arithmetic mean of the 3 serial trough sitting systolic blood pressure measurements.</description>
          <population>Full analysis set, defined as all randomized participants who received at least 1 dose of double-blind study medication, with both a baseline value and at least 1 post-baseline value, with last observation carried forward.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="153"/>
                <count group_id="O3" value="145"/>
                <count group_id="O4" value="155"/>
                <count group_id="O5" value="151"/>
                <count group_id="O6" value="158"/>
                <count group_id="O7" value="155"/>
                <count group_id="O8" value="156"/>
                <count group_id="O9" value="155"/>
                <count group_id="O10" value="152"/>
                <count group_id="O11" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.8" spread="1.26"/>
                    <measurement group_id="O2" value="-37.0" spread="1.26"/>
                    <measurement group_id="O3" value="-36.8" spread="1.30"/>
                    <measurement group_id="O4" value="-39.5" spread="1.25"/>
                    <measurement group_id="O5" value="-36.9" spread="1.27"/>
                    <measurement group_id="O6" value="-40.1" spread="1.24"/>
                    <measurement group_id="O7" value="-21.1" spread="1.25"/>
                    <measurement group_id="O8" value="-27.1" spread="1.25"/>
                    <measurement group_id="O9" value="-19.8" spread="1.26"/>
                    <measurement group_id="O10" value="-23.3" spread="1.27"/>
                    <measurement group_id="O11" value="-24.2" spread="1.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>ANCOVA using treatment as a fixed effect and baseline as a covariate was performed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Tested at 5% significance level.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-12.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.2</ci_lower_limit>
            <ci_upper_limit>-9.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>ANCOVA using treatment as a fixed effect and baseline as a covariate was performed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Tested at 5% significance level.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-9.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.4</ci_lower_limit>
            <ci_upper_limit>-6.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>ANCOVA using treatment as a fixed effect and baseline as a covariate was performed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Tested at 5% significance level.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-15.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-19.2</ci_lower_limit>
            <ci_upper_limit>-12.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>ANCOVA using treatment as a fixed effect and baseline as a covariate was performed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Tested at 5% significance level.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-12.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.8</ci_lower_limit>
            <ci_upper_limit>-8.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>ANCOVA using treatment as a fixed effect and baseline as a covariate was performed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Tested at 5% significance level.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-15.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-19.3</ci_lower_limit>
            <ci_upper_limit>-12.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>ANCOVA using treatment as a fixed effect and baseline as a covariate was performed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Tested at 5% significance level.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-13.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.5</ci_lower_limit>
            <ci_upper_limit>-9.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>ANCOVA using treatment as a fixed effect and baseline as a covariate was performed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Tested at 5% significance level.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-14.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.5</ci_lower_limit>
            <ci_upper_limit>-10.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>ANCOVA using treatment as a fixed effect and baseline as a covariate was performed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Tested at 5% significance level.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-17.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-20.6</ci_lower_limit>
            <ci_upper_limit>-13.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <groups_desc>ANCOVA using treatment as a fixed effect and baseline as a covariate was performed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Tested at 5% significance level.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-13.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.0</ci_lower_limit>
            <ci_upper_limit>-9.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <groups_desc>ANCOVA using treatment as a fixed effect and baseline as a covariate was performed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Tested at 5% significance level.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-16.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-19.7</ci_lower_limit>
            <ci_upper_limit>-12.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O11</group_id>
            </group_id_list>
            <groups_desc>ANCOVA using treatment as a fixed effect and baseline as a covariate was performed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Tested at 5% significance level.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-12.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.3</ci_lower_limit>
            <ci_upper_limit>-9.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O11</group_id>
            </group_id_list>
            <groups_desc>ANCOVA using treatment as a fixed effect and baseline as a covariate was performed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Tested at 5% significance level.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-16.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-19.4</ci_lower_limit>
            <ci_upper_limit>-12.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 8 in Trough Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring in Black Participants (Pooled Analysis)</title>
        <description>The change in trough systolic blood pressure in black subjects measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough is the average of all measurements recorded from 22 to 24 hours after dosing.</description>
        <time_frame>Baseline and Week 8.</time_frame>
        <population>Full analysis set, defined as all randomized participants who received at least 1 dose of double-blind study medication, with both a baseline value and at least 1 post-baseline value, with last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Azilsartan Medoxomil 40 mg or 80 mg/Chlorthalidone 25 mg QD</title>
            <description>Azilsartan medoxomil 40 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.
OR
Azilsartan medoxomil 80 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Chlorthalidone 25 mg QD</title>
            <description>Azilsartan medoxomil placebo and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Azilsartan Medoxomil 80 mg QD</title>
            <description>Azilsartan medoxomil 80 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 8 in Trough Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring in Black Participants (Pooled Analysis)</title>
          <description>The change in trough systolic blood pressure in black subjects measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough is the average of all measurements recorded from 22 to 24 hours after dosing.</description>
          <population>Full analysis set, defined as all randomized participants who received at least 1 dose of double-blind study medication, with both a baseline value and at least 1 post-baseline value, with last observation carried forward.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.2" spread="2.49"/>
                    <measurement group_id="O2" value="-23.4" spread="3.36"/>
                    <measurement group_id="O3" value="-9.9" spread="2.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>ANCOVA using treatment as a fixed effect and baseline as a covariate was performed. Results for Azilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QD and Azilsartan Medoxomil 80mg/Chlorthalidone 25 mg QD pool were obtained using contrast with coefficients of 0.5 for Azilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QD and 0.5 for Azilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QD from the ANCOVA model.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.255</p_value>
            <p_value_desc>Tested at 5% significance level.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-4.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.0</ci_lower_limit>
            <ci_upper_limit>3.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>ANCOVA using treatment as a fixed effect and baseline as a covariate was performed. Results for Azilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QD and Azilsartan Medoxomil 80mg/Chlorthalidone 25 mg QD pool were obtained using contrast with coefficients of 0.5 for Azilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QD and 0.5 for Azilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QD from the ANCOVA model.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Tested at 5% significance level.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-18.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-25.9</ci_lower_limit>
            <ci_upper_limit>-10.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 8 in Trough Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring in Black Participants (Pairwise Analysis)</title>
        <description>The change in trough systolic blood pressure in black participants as measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough is the average of all measurements recorded from 22 to 24 hours after dosing.</description>
        <time_frame>Baseline and Week 8.</time_frame>
        <population>Full analysis set, defined as all randomized participants who received at least 1 dose of double-blind study medication, with both a baseline value and at least 1 post-baseline value, with last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Azilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QD</title>
            <description>Azilsartan medoxomil 20 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Azilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QD</title>
            <description>Azilsartan medoxomil 20 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD</title>
            <description>Azilsartan 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Azilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QD</title>
            <description>Azilsartan medoxomil 40 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Azilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QD</title>
            <description>Azilsartan 80 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Azilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QD</title>
            <description>Azilsartan medoxomil 80 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Chlorthalidone 12.5 mg QD</title>
            <description>Azilsartan medoxomil placebo and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Chlorthalidone 25 mg QD</title>
            <description>Azilsartan medoxomil placebo and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O9">
            <title>Azilsartan Medoxomil 20 mg QD</title>
            <description>Azilsartan medoxomil 20 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O10">
            <title>Azilsartan Medoxomil 40 mg QD</title>
            <description>Azilsartan medoxomil 40 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Azilsartan Medoxomil 80 mg QD</title>
            <description>Azilsartan medoxomil 80 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 8 in Trough Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring in Black Participants (Pairwise Analysis)</title>
          <description>The change in trough systolic blood pressure in black participants as measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough is the average of all measurements recorded from 22 to 24 hours after dosing.</description>
          <population>Full analysis set, defined as all randomized participants who received at least 1 dose of double-blind study medication, with both a baseline value and at least 1 post-baseline value, with last observation carried forward.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="18"/>
                <count group_id="O6" value="21"/>
                <count group_id="O7" value="24"/>
                <count group_id="O8" value="22"/>
                <count group_id="O9" value="26"/>
                <count group_id="O10" value="27"/>
                <count group_id="O11" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.2" spread="3.21"/>
                    <measurement group_id="O2" value="-25.4" spread="3.36"/>
                    <measurement group_id="O3" value="-21.5" spread="3.21"/>
                    <measurement group_id="O4" value="-31.9" spread="3.61"/>
                    <measurement group_id="O5" value="-24.8" spread="3.71"/>
                    <measurement group_id="O6" value="-24.4" spread="3.43"/>
                    <measurement group_id="O7" value="-12.2" spread="3.22"/>
                    <measurement group_id="O8" value="-23.4" spread="3.36"/>
                    <measurement group_id="O9" value="-10.7" spread="3.10"/>
                    <measurement group_id="O10" value="-11.0" spread="3.04"/>
                    <measurement group_id="O11" value="-9.9" spread="2.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 8 in Trough, Sitting, Clinic Diastolic Blood Pressure</title>
        <description>The change in trough diastolic blood pressure measured at final visit or week 8 relative to baseline. Diastolic blood pressure is the average of the 3 serial trough clinic sitting diastolic blood pressure measurements.</description>
        <time_frame>Baseline and Week 8.</time_frame>
        <population>Full analysis set, defined as all randomized participants who received at least 1 dose of double-blind study medication, with both a baseline value and at least 1 post-baseline value, with last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Azilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QD</title>
            <description>Azilsartan medoxomil 20 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Azilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QD</title>
            <description>Azilsartan medoxomil 20 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD</title>
            <description>Azilsartan 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Azilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QD</title>
            <description>Azilsartan medoxomil 40 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Azilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QD</title>
            <description>Azilsartan 80 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Azilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QD</title>
            <description>Azilsartan medoxomil 80 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Chlorthalidone 12.5 mg QD</title>
            <description>Azilsartan medoxomil placebo and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Chlorthalidone 25 mg QD</title>
            <description>Azilsartan medoxomil placebo and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O9">
            <title>Azilsartan Medoxomil 20 mg QD</title>
            <description>Azilsartan medoxomil 20 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O10">
            <title>Azilsartan Medoxomil 40 mg QD</title>
            <description>Azilsartan medoxomil 40 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Azilsartan Medoxomil 80 mg QD</title>
            <description>Azilsartan medoxomil 80 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 8 in Trough, Sitting, Clinic Diastolic Blood Pressure</title>
          <description>The change in trough diastolic blood pressure measured at final visit or week 8 relative to baseline. Diastolic blood pressure is the average of the 3 serial trough clinic sitting diastolic blood pressure measurements.</description>
          <population>Full analysis set, defined as all randomized participants who received at least 1 dose of double-blind study medication, with both a baseline value and at least 1 post-baseline value, with last observation carried forward.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="153"/>
                <count group_id="O3" value="145"/>
                <count group_id="O4" value="155"/>
                <count group_id="O5" value="151"/>
                <count group_id="O6" value="158"/>
                <count group_id="O7" value="155"/>
                <count group_id="O8" value="156"/>
                <count group_id="O9" value="155"/>
                <count group_id="O10" value="152"/>
                <count group_id="O11" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.4" spread="0.72"/>
                    <measurement group_id="O2" value="-15.5" spread="0.72"/>
                    <measurement group_id="O3" value="-15.6" spread="0.74"/>
                    <measurement group_id="O4" value="-17.0" spread="0.72"/>
                    <measurement group_id="O5" value="-16.9" spread="0.73"/>
                    <measurement group_id="O6" value="-18.5" spread="0.71"/>
                    <measurement group_id="O7" value="-7.4" spread="0.72"/>
                    <measurement group_id="O8" value="-9.2" spread="0.72"/>
                    <measurement group_id="O9" value="-6.7" spread="0.72"/>
                    <measurement group_id="O10" value="-9.2" spread="0.73"/>
                    <measurement group_id="O11" value="-9.9" spread="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 8 in the Mean Trough Diastolic Blood Pressure (22 to 24 Hours After Dosing), as Measured by Ambulatory Blood Pressure Monitoring.</title>
        <description>The change in trough diastolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough is the average of all measurements recorded from 22 to 24 hours after dosing.</description>
        <time_frame>Baseline and Week 8.</time_frame>
        <population>Full analysis set, defined as all randomized participants who received at least 1 dose of double-blind study medication, with both a baseline value and at least 1 post-baseline value, with last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Azilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QD</title>
            <description>Azilsartan medoxomil 20 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Azilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QD</title>
            <description>Azilsartan medoxomil 20 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD</title>
            <description>Azilsartan 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Azilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QD</title>
            <description>Azilsartan medoxomil 40 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Azilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QD</title>
            <description>Azilsartan 80 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Azilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QD</title>
            <description>Azilsartan medoxomil 80 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Chlorthalidone 12.5 mg QD</title>
            <description>Azilsartan medoxomil placebo and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Chlorthalidone 25 mg QD</title>
            <description>Azilsartan medoxomil placebo and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O9">
            <title>Azilsartan Medoxomil 20 mg QD</title>
            <description>Azilsartan medoxomil 20 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O10">
            <title>Azilsartan Medoxomil 40 mg QD</title>
            <description>Azilsartan medoxomil 40 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Azilsartan Medoxomil 80 mg QD</title>
            <description>Azilsartan medoxomil 80 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 8 in the Mean Trough Diastolic Blood Pressure (22 to 24 Hours After Dosing), as Measured by Ambulatory Blood Pressure Monitoring.</title>
          <description>The change in trough diastolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough is the average of all measurements recorded from 22 to 24 hours after dosing.</description>
          <population>Full analysis set, defined as all randomized participants who received at least 1 dose of double-blind study medication, with both a baseline value and at least 1 post-baseline value, with last observation carried forward.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="118"/>
                <count group_id="O3" value="117"/>
                <count group_id="O4" value="114"/>
                <count group_id="O5" value="110"/>
                <count group_id="O6" value="114"/>
                <count group_id="O7" value="130"/>
                <count group_id="O8" value="134"/>
                <count group_id="O9" value="128"/>
                <count group_id="O10" value="131"/>
                <count group_id="O11" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.3" spread="0.80"/>
                    <measurement group_id="O2" value="-15.0" spread="0.83"/>
                    <measurement group_id="O3" value="-13.5" spread="0.83"/>
                    <measurement group_id="O4" value="-17.3" spread="0.85"/>
                    <measurement group_id="O5" value="-16.5" spread="0.86"/>
                    <measurement group_id="O6" value="-16.1" spread="0.85"/>
                    <measurement group_id="O7" value="-6.5" spread="0.79"/>
                    <measurement group_id="O8" value="-7.5" spread="0.78"/>
                    <measurement group_id="O9" value="-7.9" spread="0.80"/>
                    <measurement group_id="O10" value="-7.3" spread="0.79"/>
                    <measurement group_id="O11" value="-8.9" spread="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 8 in the 24-hour Mean Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring</title>
        <description>The change in 24-hour mean systolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.</description>
        <time_frame>Baseline and Week 8.</time_frame>
        <population>Full analysis set, defined as all randomized participants who received at least 1 dose of double-blind study medication, with both a baseline value and at least 1 post-baseline value, with last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Azilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QD</title>
            <description>Azilsartan medoxomil 20 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Azilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QD</title>
            <description>Azilsartan medoxomil 20 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD</title>
            <description>Azilsartan 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Azilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QD</title>
            <description>Azilsartan medoxomil 40 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Azilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QD</title>
            <description>Azilsartan 80 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Azilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QD</title>
            <description>Azilsartan medoxomil 80 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Chlorthalidone 12.5 mg QD</title>
            <description>Azilsartan medoxomil placebo and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Chlorthalidone 25 mg QD</title>
            <description>Azilsartan medoxomil placebo and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O9">
            <title>Azilsartan Medoxomil 20 mg QD</title>
            <description>Azilsartan medoxomil 20 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O10">
            <title>Azilsartan Medoxomil 40 mg QD</title>
            <description>Azilsartan medoxomil 40 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Azilsartan Medoxomil 80 mg QD</title>
            <description>Azilsartan medoxomil 80 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 8 in the 24-hour Mean Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring</title>
          <description>The change in 24-hour mean systolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.</description>
          <population>Full analysis set, defined as all randomized participants who received at least 1 dose of double-blind study medication, with both a baseline value and at least 1 post-baseline value, with last observation carried forward.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="118"/>
                <count group_id="O3" value="117"/>
                <count group_id="O4" value="114"/>
                <count group_id="O5" value="110"/>
                <count group_id="O6" value="114"/>
                <count group_id="O7" value="130"/>
                <count group_id="O8" value="134"/>
                <count group_id="O9" value="128"/>
                <count group_id="O10" value="131"/>
                <count group_id="O11" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.0" spread="0.97"/>
                    <measurement group_id="O2" value="-26.7" spread="1.01"/>
                    <measurement group_id="O3" value="-26.1" spread="1.01"/>
                    <measurement group_id="O4" value="-30.4" spread="1.03"/>
                    <measurement group_id="O5" value="-27.9" spread="1.04"/>
                    <measurement group_id="O6" value="-28.1" spread="1.03"/>
                    <measurement group_id="O7" value="-10.9" spread="0.96"/>
                    <measurement group_id="O8" value="-14.7" spread="0.95"/>
                    <measurement group_id="O9" value="-11.7" spread="0.97"/>
                    <measurement group_id="O10" value="-12.6" spread="0.96"/>
                    <measurement group_id="O11" value="-15.3" spread="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 8 in the 24-hour Mean Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring</title>
        <description>The change in 24-hour mean diastolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.</description>
        <time_frame>Baseline and Week 8.</time_frame>
        <population>Full analysis set, defined as all randomized participants who received at least 1 dose of double-blind study medication, with both a baseline value and at least 1 post-baseline value, with last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Azilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QD</title>
            <description>Azilsartan medoxomil 20 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Azilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QD</title>
            <description>Azilsartan medoxomil 20 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD</title>
            <description>Azilsartan 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Azilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QD</title>
            <description>Azilsartan medoxomil 40 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Azilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QD</title>
            <description>Azilsartan 80 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Azilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QD</title>
            <description>Azilsartan medoxomil 80 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Chlorthalidone 12.5 mg QD</title>
            <description>Azilsartan medoxomil placebo and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Chlorthalidone 25 mg QD</title>
            <description>Azilsartan medoxomil placebo and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O9">
            <title>Azilsartan Medoxomil 20 mg QD</title>
            <description>Azilsartan medoxomil 20 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O10">
            <title>Azilsartan Medoxomil 40 mg QD</title>
            <description>Azilsartan medoxomil 40 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Azilsartan Medoxomil 80 mg QD</title>
            <description>Azilsartan medoxomil 80 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 8 in the 24-hour Mean Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring</title>
          <description>The change in 24-hour mean diastolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.</description>
          <population>Full analysis set, defined as all randomized participants who received at least 1 dose of double-blind study medication, with both a baseline value and at least 1 post-baseline value, with last observation carried forward.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="118"/>
                <count group_id="O3" value="117"/>
                <count group_id="O4" value="114"/>
                <count group_id="O5" value="110"/>
                <count group_id="O6" value="114"/>
                <count group_id="O7" value="130"/>
                <count group_id="O8" value="134"/>
                <count group_id="O9" value="128"/>
                <count group_id="O10" value="131"/>
                <count group_id="O11" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.5" spread="0.60"/>
                    <measurement group_id="O2" value="-15.0" spread="0.62"/>
                    <measurement group_id="O3" value="-14.9" spread="0.63"/>
                    <measurement group_id="O4" value="-17.3" spread="0.64"/>
                    <measurement group_id="O5" value="-16.5" spread="0.65"/>
                    <measurement group_id="O6" value="-15.9" spread="0.64"/>
                    <measurement group_id="O7" value="-5.6" spread="0.59"/>
                    <measurement group_id="O8" value="-6.7" spread="0.59"/>
                    <measurement group_id="O9" value="-6.8" spread="0.60"/>
                    <measurement group_id="O10" value="-7.6" spread="0.59"/>
                    <measurement group_id="O11" value="-8.8" spread="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 8 in the Mean Daytime (6 AM to 10 PM) Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring.</title>
        <description>The change in daytime (6am to 10pm) mean systolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.</description>
        <time_frame>Baseline and Week 8.</time_frame>
        <population>Full analysis set, defined as all randomized participants who received at least 1 dose of double-blind study medication, with both a baseline value and at least 1 post-baseline value, with last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Azilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QD</title>
            <description>Azilsartan medoxomil 20 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Azilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QD</title>
            <description>Azilsartan medoxomil 20 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD</title>
            <description>Azilsartan 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Azilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QD</title>
            <description>Azilsartan medoxomil 40 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Azilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QD</title>
            <description>Azilsartan 80 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Azilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QD</title>
            <description>Azilsartan medoxomil 80 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Chlorthalidone 12.5 mg QD</title>
            <description>Azilsartan medoxomil placebo and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Chlorthalidone 25 mg QD</title>
            <description>Azilsartan medoxomil placebo and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O9">
            <title>Azilsartan Medoxomil 20 mg QD</title>
            <description>Azilsartan medoxomil 20 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O10">
            <title>Azilsartan Medoxomil 40 mg QD</title>
            <description>Azilsartan medoxomil 40 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Azilsartan Medoxomil 80 mg QD</title>
            <description>Azilsartan medoxomil 80 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 8 in the Mean Daytime (6 AM to 10 PM) Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring.</title>
          <description>The change in daytime (6am to 10pm) mean systolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.</description>
          <population>Full analysis set, defined as all randomized participants who received at least 1 dose of double-blind study medication, with both a baseline value and at least 1 post-baseline value, with last observation carried forward.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="118"/>
                <count group_id="O3" value="117"/>
                <count group_id="O4" value="114"/>
                <count group_id="O5" value="110"/>
                <count group_id="O6" value="114"/>
                <count group_id="O7" value="130"/>
                <count group_id="O8" value="134"/>
                <count group_id="O9" value="128"/>
                <count group_id="O10" value="131"/>
                <count group_id="O11" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.4" spread="1.01"/>
                    <measurement group_id="O2" value="-27.7" spread="1.05"/>
                    <measurement group_id="O3" value="-26.7" spread="1.06"/>
                    <measurement group_id="O4" value="-31.2" spread="1.07"/>
                    <measurement group_id="O5" value="-28.4" spread="1.09"/>
                    <measurement group_id="O6" value="-28.5" spread="1.07"/>
                    <measurement group_id="O7" value="-10.8" spread="1.00"/>
                    <measurement group_id="O8" value="-14.7" spread="0.99"/>
                    <measurement group_id="O9" value="-11.7" spread="1.01"/>
                    <measurement group_id="O10" value="-12.8" spread="1.00"/>
                    <measurement group_id="O11" value="-15.7" spread="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 8 in the Mean Daytime (6 AM to 10 PM) Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring.</title>
        <description>The change in daytime (6am to 10pm) mean diastolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.</description>
        <time_frame>Baseline and Week 8.</time_frame>
        <population>Full analysis set, defined as all randomized participants who received at least 1 dose of double-blind study medication, with both a baseline value and at least 1 post-baseline value, with last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Azilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QD</title>
            <description>Azilsartan medoxomil 20 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Azilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QD</title>
            <description>Azilsartan medoxomil 20 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD</title>
            <description>Azilsartan 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Azilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QD</title>
            <description>Azilsartan medoxomil 40 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Azilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QD</title>
            <description>Azilsartan 80 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Azilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QD</title>
            <description>Azilsartan medoxomil 80 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Chlorthalidone 12.5 mg QD</title>
            <description>Azilsartan medoxomil placebo and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Chlorthalidone 25 mg QD</title>
            <description>Azilsartan medoxomil placebo and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O9">
            <title>Azilsartan Medoxomil 20 mg QD</title>
            <description>Azilsartan medoxomil 20 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O10">
            <title>Azilsartan Medoxomil 40 mg QD</title>
            <description>Azilsartan medoxomil 40 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Azilsartan Medoxomil 80 mg QD</title>
            <description>Azilsartan medoxomil 80 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 8 in the Mean Daytime (6 AM to 10 PM) Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring.</title>
          <description>The change in daytime (6am to 10pm) mean diastolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.</description>
          <population>Full analysis set, defined as all randomized participants who received at least 1 dose of double-blind study medication, with both a baseline value and at least 1 post-baseline value, with last observation carried forward.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="118"/>
                <count group_id="O3" value="117"/>
                <count group_id="O4" value="114"/>
                <count group_id="O5" value="110"/>
                <count group_id="O6" value="114"/>
                <count group_id="O7" value="130"/>
                <count group_id="O8" value="134"/>
                <count group_id="O9" value="128"/>
                <count group_id="O10" value="131"/>
                <count group_id="O11" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.7" spread="0.64"/>
                    <measurement group_id="O2" value="-15.6" spread="0.66"/>
                    <measurement group_id="O3" value="-15.1" spread="0.66"/>
                    <measurement group_id="O4" value="-17.6" spread="0.67"/>
                    <measurement group_id="O5" value="-16.8" spread="0.69"/>
                    <measurement group_id="O6" value="-16.2" spread="0.67"/>
                    <measurement group_id="O7" value="-5.6" spread="0.63"/>
                    <measurement group_id="O8" value="-6.5" spread="0.62"/>
                    <measurement group_id="O9" value="-6.8" spread="0.64"/>
                    <measurement group_id="O10" value="-7.7" spread="0.63"/>
                    <measurement group_id="O11" value="-9.1" spread="0.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 8 in the Mean Nighttime (12 AM to 6 AM) Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring.</title>
        <description>The change in nighttime (12am to 6am) mean systolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.</description>
        <time_frame>Baseline and Week 8.</time_frame>
        <population>Full analysis set, defined as all randomized participants who received at least 1 dose of double-blind study medication, with both a baseline value and at least 1 post-baseline value, with last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Azilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QD</title>
            <description>Azilsartan medoxomil 20 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Azilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QD</title>
            <description>Azilsartan medoxomil 20 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD</title>
            <description>Azilsartan 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Azilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QD</title>
            <description>Azilsartan medoxomil 40 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Azilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QD</title>
            <description>Azilsartan 80 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Azilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QD</title>
            <description>Azilsartan medoxomil 80 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Chlorthalidone 12.5 mg QD</title>
            <description>Azilsartan medoxomil placebo and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Chlorthalidone 25 mg QD</title>
            <description>Azilsartan medoxomil placebo and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O9">
            <title>Azilsartan Medoxomil 20 mg QD</title>
            <description>Azilsartan medoxomil 20 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O10">
            <title>Azilsartan Medoxomil 40 mg QD</title>
            <description>Azilsartan medoxomil 40 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Azilsartan Medoxomil 80 mg QD</title>
            <description>Azilsartan medoxomil 80 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 8 in the Mean Nighttime (12 AM to 6 AM) Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring.</title>
          <description>The change in nighttime (12am to 6am) mean systolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.</description>
          <population>Full analysis set, defined as all randomized participants who received at least 1 dose of double-blind study medication, with both a baseline value and at least 1 post-baseline value, with last observation carried forward.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="118"/>
                <count group_id="O3" value="117"/>
                <count group_id="O4" value="114"/>
                <count group_id="O5" value="110"/>
                <count group_id="O6" value="114"/>
                <count group_id="O7" value="130"/>
                <count group_id="O8" value="134"/>
                <count group_id="O9" value="128"/>
                <count group_id="O10" value="131"/>
                <count group_id="O11" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.5" spread="1.09"/>
                    <measurement group_id="O2" value="-24.0" spread="1.13"/>
                    <measurement group_id="O3" value="-24.3" spread="1.14"/>
                    <measurement group_id="O4" value="-28.1" spread="1.15"/>
                    <measurement group_id="O5" value="-26.5" spread="1.17"/>
                    <measurement group_id="O6" value="-26.3" spread="1.15"/>
                    <measurement group_id="O7" value="-11.3" spread="1.08"/>
                    <measurement group_id="O8" value="-14.4" spread="1.06"/>
                    <measurement group_id="O9" value="-11.8" spread="1.09"/>
                    <measurement group_id="O10" value="-11.8" spread="1.08"/>
                    <measurement group_id="O11" value="-14.2" spread="1.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 8 in the Mean Nighttime (12 AM to 6 AM) Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring.</title>
        <description>The change in nighttime (12am to 6am) mean diastolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.</description>
        <time_frame>Baseline and Week 8.</time_frame>
        <population>Full analysis set, defined as all randomized participants who received at least 1 dose of double-blind study medication, with both a baseline value and at least 1 post-baseline value, with last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Azilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QD</title>
            <description>Azilsartan medoxomil 20 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Azilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QD</title>
            <description>Azilsartan medoxomil 20 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD</title>
            <description>Azilsartan 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Azilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QD</title>
            <description>Azilsartan medoxomil 40 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Azilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QD</title>
            <description>Azilsartan 80 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Azilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QD</title>
            <description>Azilsartan medoxomil 80 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Chlorthalidone 12.5 mg QD</title>
            <description>Azilsartan medoxomil placebo and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Chlorthalidone 25 mg QD</title>
            <description>Azilsartan medoxomil placebo and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O9">
            <title>Azilsartan Medoxomil 20 mg QD</title>
            <description>Azilsartan medoxomil 20 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O10">
            <title>Azilsartan Medoxomil 40 mg QD</title>
            <description>Azilsartan medoxomil 40 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Azilsartan Medoxomil 80 mg QD</title>
            <description>Azilsartan medoxomil 80 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 8 in the Mean Nighttime (12 AM to 6 AM) Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring.</title>
          <description>The change in nighttime (12am to 6am) mean diastolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.</description>
          <population>Full analysis set, defined as all randomized participants who received at least 1 dose of double-blind study medication, with both a baseline value and at least 1 post-baseline value, with last observation carried forward.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="118"/>
                <count group_id="O3" value="117"/>
                <count group_id="O4" value="114"/>
                <count group_id="O5" value="110"/>
                <count group_id="O6" value="114"/>
                <count group_id="O7" value="130"/>
                <count group_id="O8" value="134"/>
                <count group_id="O9" value="128"/>
                <count group_id="O10" value="131"/>
                <count group_id="O11" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.8" spread="0.71"/>
                    <measurement group_id="O2" value="-13.5" spread="0.73"/>
                    <measurement group_id="O3" value="-14.4" spread="0.74"/>
                    <measurement group_id="O4" value="-16.2" spread="0.75"/>
                    <measurement group_id="O5" value="-15.8" spread="0.76"/>
                    <measurement group_id="O6" value="-14.9" spread="0.75"/>
                    <measurement group_id="O7" value="-6.0" spread="0.70"/>
                    <measurement group_id="O8" value="-7.1" spread="0.69"/>
                    <measurement group_id="O9" value="-6.9" spread="0.70"/>
                    <measurement group_id="O10" value="-7.5" spread="0.69"/>
                    <measurement group_id="O11" value="-8.0" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 8 in the Mean Systolic Blood Pressure at 0 to 12 Hours After Dosing, as Measured by Ambulatory Blood Pressure Monitoring.</title>
        <description>The change in the 12-hour mean systolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing.</description>
        <time_frame>Baseline and Week 8</time_frame>
        <population>Full analysis set, defined as all randomized participants who received at least 1 dose of double-blind study medication, with both a baseline value and at least 1 post-baseline value, with last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Azilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QD</title>
            <description>Azilsartan medoxomil 20 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Azilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QD</title>
            <description>Azilsartan medoxomil 20 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD</title>
            <description>Azilsartan 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Azilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QD</title>
            <description>Azilsartan medoxomil 40 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Azilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QD</title>
            <description>Azilsartan 80 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Azilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QD</title>
            <description>Azilsartan medoxomil 80 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Chlorthalidone 12.5 mg QD</title>
            <description>Azilsartan medoxomil placebo and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Chlorthalidone 25 mg QD</title>
            <description>Azilsartan medoxomil placebo and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O9">
            <title>Azilsartan Medoxomil 20 mg QD</title>
            <description>Azilsartan medoxomil 20 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O10">
            <title>Azilsartan Medoxomil 40 mg QD</title>
            <description>Azilsartan medoxomil 40 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Azilsartan Medoxomil 80 mg QD</title>
            <description>Azilsartan medoxomil 80 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 8 in the Mean Systolic Blood Pressure at 0 to 12 Hours After Dosing, as Measured by Ambulatory Blood Pressure Monitoring.</title>
          <description>The change in the 12-hour mean systolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing.</description>
          <population>Full analysis set, defined as all randomized participants who received at least 1 dose of double-blind study medication, with both a baseline value and at least 1 post-baseline value, with last observation carried forward.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="118"/>
                <count group_id="O3" value="117"/>
                <count group_id="O4" value="114"/>
                <count group_id="O5" value="110"/>
                <count group_id="O6" value="114"/>
                <count group_id="O7" value="130"/>
                <count group_id="O8" value="134"/>
                <count group_id="O9" value="128"/>
                <count group_id="O10" value="131"/>
                <count group_id="O11" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.6" spread="1.07"/>
                    <measurement group_id="O2" value="-28.0" spread="1.11"/>
                    <measurement group_id="O3" value="-27.1" spread="1.12"/>
                    <measurement group_id="O4" value="-31.7" spread="1.13"/>
                    <measurement group_id="O5" value="-28.5" spread="1.15"/>
                    <measurement group_id="O6" value="-28.7" spread="1.13"/>
                    <measurement group_id="O7" value="-10.4" spread="1.06"/>
                    <measurement group_id="O8" value="-14.5" spread="1.04"/>
                    <measurement group_id="O9" value="-11.8" spread="1.07"/>
                    <measurement group_id="O10" value="-12.7" spread="1.05"/>
                    <measurement group_id="O11" value="-15.8" spread="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 8 in the Mean Diastolic Blood Pressure at 0 to 12 Hours After Dosing, as Measured by Ambulatory Blood Pressure Monitoring.</title>
        <description>The change in the 12-hour mean diastolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing.</description>
        <time_frame>Baseline and Week 8.</time_frame>
        <population>Full analysis set, defined as all randomized participants who received at least 1 dose of double-blind study medication, with both a baseline value and at least 1 post-baseline value, with last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Azilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QD</title>
            <description>Azilsartan medoxomil 20 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Azilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QD</title>
            <description>Azilsartan medoxomil 20 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD</title>
            <description>Azilsartan 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Azilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QD</title>
            <description>Azilsartan medoxomil 40 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Azilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QD</title>
            <description>Azilsartan 80 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Azilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QD</title>
            <description>Azilsartan medoxomil 80 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Chlorthalidone 12.5 mg QD</title>
            <description>Azilsartan medoxomil placebo and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Chlorthalidone 25 mg QD</title>
            <description>Azilsartan medoxomil placebo and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O9">
            <title>Azilsartan Medoxomil 20 mg QD</title>
            <description>Azilsartan medoxomil 20 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O10">
            <title>Azilsartan Medoxomil 40 mg QD</title>
            <description>Azilsartan medoxomil 40 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Azilsartan Medoxomil 80 mg QD</title>
            <description>Azilsartan medoxomil 80 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 8 in the Mean Diastolic Blood Pressure at 0 to 12 Hours After Dosing, as Measured by Ambulatory Blood Pressure Monitoring.</title>
          <description>The change in the 12-hour mean diastolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing.</description>
          <population>Full analysis set, defined as all randomized participants who received at least 1 dose of double-blind study medication, with both a baseline value and at least 1 post-baseline value, with last observation carried forward.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="118"/>
                <count group_id="O3" value="117"/>
                <count group_id="O4" value="114"/>
                <count group_id="O5" value="110"/>
                <count group_id="O6" value="114"/>
                <count group_id="O7" value="130"/>
                <count group_id="O8" value="134"/>
                <count group_id="O9" value="128"/>
                <count group_id="O10" value="131"/>
                <count group_id="O11" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.6" spread="0.68"/>
                    <measurement group_id="O2" value="-15.6" spread="0.71"/>
                    <measurement group_id="O3" value="-15.4" spread="0.71"/>
                    <measurement group_id="O4" value="-17.8" spread="0.72"/>
                    <measurement group_id="O5" value="-16.8" spread="0.73"/>
                    <measurement group_id="O6" value="-16.2" spread="0.72"/>
                    <measurement group_id="O7" value="-5.3" spread="0.67"/>
                    <measurement group_id="O8" value="-6.3" spread="0.66"/>
                    <measurement group_id="O9" value="-6.8" spread="0.68"/>
                    <measurement group_id="O10" value="-7.6" spread="0.67"/>
                    <measurement group_id="O11" value="-9.2" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Achieve a Clinic Systolic Blood Pressure Response at Week 8, as Defined by Clinic Systolic Blood Pressure &lt;140 mm Hg and/or a Reduction of ≥20 mm Hg From Baseline.</title>
        <description>Percentage of participants who achieve a clinic systolic blood pressure response measured at week 8, defined as less than 140 mm Hg and/or reduction from baseline of greater than or equal to 20 mm Hg. Systolic blood pressure is the average of the 3 serial trough sitting clinic systolic blood pressure measurements.</description>
        <time_frame>Baseline and Week 8</time_frame>
        <population>Full analysis set, defined as all randomized participants who received at least 1 dose of double-blind study medication, with both a baseline value and at least 1 post-baseline value, with last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Azilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QD</title>
            <description>Azilsartan medoxomil 20 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Azilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QD</title>
            <description>Azilsartan medoxomil 20 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD</title>
            <description>Azilsartan 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Azilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QD</title>
            <description>Azilsartan medoxomil 40 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Azilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QD</title>
            <description>Azilsartan 80 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Azilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QD</title>
            <description>Azilsartan medoxomil 80 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Chlorthalidone 12.5 mg QD</title>
            <description>Azilsartan medoxomil placebo and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Chlorthalidone 25 mg QD</title>
            <description>Azilsartan medoxomil placebo and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O9">
            <title>Azilsartan Medoxomil 20 mg QD</title>
            <description>Azilsartan medoxomil 20 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O10">
            <title>Azilsartan Medoxomil 40 mg QD</title>
            <description>Azilsartan medoxomil 40 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Azilsartan Medoxomil 80 mg QD</title>
            <description>Azilsartan medoxomil 80 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieve a Clinic Systolic Blood Pressure Response at Week 8, as Defined by Clinic Systolic Blood Pressure &lt;140 mm Hg and/or a Reduction of ≥20 mm Hg From Baseline.</title>
          <description>Percentage of participants who achieve a clinic systolic blood pressure response measured at week 8, defined as less than 140 mm Hg and/or reduction from baseline of greater than or equal to 20 mm Hg. Systolic blood pressure is the average of the 3 serial trough sitting clinic systolic blood pressure measurements.</description>
          <population>Full analysis set, defined as all randomized participants who received at least 1 dose of double-blind study medication, with both a baseline value and at least 1 post-baseline value, with last observation carried forward.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="153"/>
                <count group_id="O3" value="145"/>
                <count group_id="O4" value="155"/>
                <count group_id="O5" value="151"/>
                <count group_id="O6" value="158"/>
                <count group_id="O7" value="155"/>
                <count group_id="O8" value="156"/>
                <count group_id="O9" value="155"/>
                <count group_id="O10" value="152"/>
                <count group_id="O11" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.4"/>
                    <measurement group_id="O2" value="88.9"/>
                    <measurement group_id="O3" value="90.3"/>
                    <measurement group_id="O4" value="93.5"/>
                    <measurement group_id="O5" value="86.8"/>
                    <measurement group_id="O6" value="94.9"/>
                    <measurement group_id="O7" value="56.1"/>
                    <measurement group_id="O8" value="76.9"/>
                    <measurement group_id="O9" value="53.5"/>
                    <measurement group_id="O10" value="64.5"/>
                    <measurement group_id="O11" value="66.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to Week 8 in Trough, Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring (Pairwise Analysis)</title>
        <description>The change in trough systolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough is the average of all measurements recorded from 22 to 24 hours after dosing.</description>
        <time_frame>Baseline and Week 8.</time_frame>
        <population>Full analysis set, defined as all randomized participants who received at least 1 dose of double-blind study medication, with both a baseline value and at least 1 post-baseline value, with last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Azilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QD</title>
            <description>Azilsartan medoxomil 20 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Azilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QD</title>
            <description>Azilsartan medoxomil 20 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD</title>
            <description>Azilsartan 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Azilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QD</title>
            <description>Azilsartan medoxomil 40 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Azilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QD</title>
            <description>Azilsartan 80 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Azilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QD</title>
            <description>Azilsartan medoxomil 80 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Chlorthalidone 12.5 mg QD</title>
            <description>Azilsartan medoxomil placebo and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Chlorthalidone 25 mg QD</title>
            <description>Azilsartan medoxomil placebo and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O9">
            <title>Azilsartan Medoxomil 20 mg QD</title>
            <description>Azilsartan medoxomil 20 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O10">
            <title>Azilsartan Medoxomil 40 mg QD</title>
            <description>Azilsartan medoxomil 40 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Azilsartan Medoxomil 80 mg QD</title>
            <description>Azilsartan medoxomil 80 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 8 in Trough, Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring (Pairwise Analysis)</title>
          <description>The change in trough systolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough is the average of all measurements recorded from 22 to 24 hours after dosing.</description>
          <population>Full analysis set, defined as all randomized participants who received at least 1 dose of double-blind study medication, with both a baseline value and at least 1 post-baseline value, with last observation carried forward.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="118"/>
                <count group_id="O3" value="117"/>
                <count group_id="O4" value="114"/>
                <count group_id="O5" value="110"/>
                <count group_id="O6" value="114"/>
                <count group_id="O7" value="130"/>
                <count group_id="O8" value="134"/>
                <count group_id="O9" value="128"/>
                <count group_id="O10" value="131"/>
                <count group_id="O11" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.9" spread="1.19"/>
                    <measurement group_id="O2" value="-26.3" spread="1.24"/>
                    <measurement group_id="O3" value="-24.4" spread="1.24"/>
                    <measurement group_id="O4" value="-29.8" spread="1.26"/>
                    <measurement group_id="O5" value="-26.3" spread="1.28"/>
                    <measurement group_id="O6" value="-28.0" spread="1.26"/>
                    <measurement group_id="O7" value="-12.7" spread="1.18"/>
                    <measurement group_id="O8" value="-15.9" spread="1.16"/>
                    <measurement group_id="O9" value="-12.1" spread="1.19"/>
                    <measurement group_id="O10" value="-12.8" spread="1.17"/>
                    <measurement group_id="O11" value="-15.1" spread="1.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>ANCOVA using treatment as a fixed effect and baseline as a covariate was performed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>Tested at 5% significance level.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-10.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.6</ci_lower_limit>
            <ci_upper_limit>-7.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>ANCOVA using treatment as a fixed effect and baseline as a covariate was performed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Tested at 5% significance level.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-10.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.7</ci_lower_limit>
            <ci_upper_limit>-7.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>ANCOVA using treatment as a fixed effect and baseline as a covariate was performed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Tested at 5% significance level.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-11.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.1</ci_lower_limit>
            <ci_upper_limit>-8.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>ANCOVA using treatment as a fixed effect and baseline as a covariate was performed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Tested at 5% significance level.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-13.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.3</ci_lower_limit>
            <ci_upper_limit>-10.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>ANCOVA using treatment as a fixed effect and baseline as a covariate was performed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Tested at 5% significance level.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-13.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.1</ci_lower_limit>
            <ci_upper_limit>-10.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>ANCOVA using treatment as a fixed effect and baseline as a covariate was performed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Tested at 5% significance level.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-12.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.4</ci_lower_limit>
            <ci_upper_limit>-8.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>ANCOVA using treatment as a fixed effect and baseline as a covariate was performed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Tested at 5% significance level.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-10.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.2</ci_lower_limit>
            <ci_upper_limit>-7.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>ANCOVA using treatment as a fixed effect and baseline as a covariate was performed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Tested at 5% significance level.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-14.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.6</ci_lower_limit>
            <ci_upper_limit>-10.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <groups_desc>ANCOVA using treatment as a fixed effect and baseline as a covariate was performed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Tested at 5% significance level.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-11.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.0</ci_lower_limit>
            <ci_upper_limit>-8.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <groups_desc>ANCOVA using treatment as a fixed effect and baseline as a covariate was performed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Tested at 5% significance level.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-17.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-20.4</ci_lower_limit>
            <ci_upper_limit>-13.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O11</group_id>
            </group_id_list>
            <groups_desc>ANCOVA using treatment as a fixed effect and baseline as a covariate was performed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Tested at 5% significance level.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-11.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.7</ci_lower_limit>
            <ci_upper_limit>-7.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O11</group_id>
            </group_id_list>
            <groups_desc>ANCOVA using treatment as a fixed effect and baseline as a covariate was performed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Tested at 5% significance level.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-12.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.2</ci_lower_limit>
            <ci_upper_limit>-9.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Achieve a Clinic Diastolic Blood Pressure Response at Week 8, Defined as Clinic Diastolic Blood Pressure &lt;90 mm Hg and/or a Reduction of ≥10 mm Hg From Baseline.</title>
        <description>Percentage of participants who achieve a clinic diastolic blood pressure response measured at week 8, defined as less than 90 mm Hg and/or reduction from baseline of greater than or equal to 10 mm Hg. Diastolic blood pressure is the average of the 3 serial trough sitting clinic diastolic blood pressure measurements.</description>
        <time_frame>Baseline and Week 8.</time_frame>
        <population>Full analysis set, defined as all randomized participants who received at least 1 dose of double-blind study medication, with both a baseline value and at least 1 post-baseline value, with last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Azilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QD</title>
            <description>Azilsartan medoxomil 20 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Azilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QD</title>
            <description>Azilsartan medoxomil 20 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD</title>
            <description>Azilsartan 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Azilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QD</title>
            <description>Azilsartan medoxomil 40 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Azilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QD</title>
            <description>Azilsartan 80 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Azilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QD</title>
            <description>Azilsartan medoxomil 80 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Chlorthalidone 12.5 mg QD</title>
            <description>Azilsartan medoxomil placebo and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Chlorthalidone 25 mg QD</title>
            <description>Azilsartan medoxomil placebo and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O9">
            <title>Azilsartan Medoxomil 20 mg QD</title>
            <description>Azilsartan medoxomil 20 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O10">
            <title>Azilsartan Medoxomil 40 mg QD</title>
            <description>Azilsartan medoxomil 40 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Azilsartan Medoxomil 80 mg QD</title>
            <description>Azilsartan medoxomil 80 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieve a Clinic Diastolic Blood Pressure Response at Week 8, Defined as Clinic Diastolic Blood Pressure &lt;90 mm Hg and/or a Reduction of ≥10 mm Hg From Baseline.</title>
          <description>Percentage of participants who achieve a clinic diastolic blood pressure response measured at week 8, defined as less than 90 mm Hg and/or reduction from baseline of greater than or equal to 10 mm Hg. Diastolic blood pressure is the average of the 3 serial trough sitting clinic diastolic blood pressure measurements.</description>
          <population>Full analysis set, defined as all randomized participants who received at least 1 dose of double-blind study medication, with both a baseline value and at least 1 post-baseline value, with last observation carried forward.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="153"/>
                <count group_id="O3" value="145"/>
                <count group_id="O4" value="155"/>
                <count group_id="O5" value="151"/>
                <count group_id="O6" value="158"/>
                <count group_id="O7" value="155"/>
                <count group_id="O8" value="156"/>
                <count group_id="O9" value="155"/>
                <count group_id="O10" value="152"/>
                <count group_id="O11" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.6"/>
                    <measurement group_id="O2" value="89.5"/>
                    <measurement group_id="O3" value="87.6"/>
                    <measurement group_id="O4" value="94.8"/>
                    <measurement group_id="O5" value="90.1"/>
                    <measurement group_id="O6" value="96.8"/>
                    <measurement group_id="O7" value="63.9"/>
                    <measurement group_id="O8" value="78.8"/>
                    <measurement group_id="O9" value="60.6"/>
                    <measurement group_id="O10" value="71.1"/>
                    <measurement group_id="O11" value="74.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Achieve Both a Clinic Systolic and Diastolic Blood Pressure Response at Week 8.</title>
        <description>Percentage of participants who achieve both a clinic systolic and diastolic blood pressure response measured at week 8, defined as systolic blood pressure less than 140 mm Hg and/or reduction from baseline of greater than or equal to 20 mm Hg AND diastolic blood pressure less than 90 mm Hg and/or reduction from baseline of greater than or equal to 10 mm Hg . Systolic/diastolic blood pressure is based on the average of the 3 serial trough clinic sitting systolic/diastolic blood pressure measurements.</description>
        <time_frame>Baseline and Week 8.</time_frame>
        <population>Full analysis set, defined as all randomized participants who received at least 1 dose of double-blind study medication, with both a baseline value and at least 1 post-baseline value, with last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Azilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QD</title>
            <description>Azilsartan medoxomil 20 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Azilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QD</title>
            <description>Azilsartan medoxomil 20 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD</title>
            <description>Azilsartan 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Azilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QD</title>
            <description>Azilsartan medoxomil 40 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Azilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QD</title>
            <description>Azilsartan 80 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Azilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QD</title>
            <description>Azilsartan medoxomil 80 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Chlorthalidone 12.5 mg QD</title>
            <description>Azilsartan medoxomil placebo and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Chlorthalidone 25 mg QD</title>
            <description>Azilsartan medoxomil placebo and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O9">
            <title>Azilsartan Medoxomil 20 mg QD</title>
            <description>Azilsartan medoxomil 20 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O10">
            <title>Azilsartan Medoxomil 40 mg QD</title>
            <description>Azilsartan medoxomil 40 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Azilsartan Medoxomil 80 mg QD</title>
            <description>Azilsartan medoxomil 80 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieve Both a Clinic Systolic and Diastolic Blood Pressure Response at Week 8.</title>
          <description>Percentage of participants who achieve both a clinic systolic and diastolic blood pressure response measured at week 8, defined as systolic blood pressure less than 140 mm Hg and/or reduction from baseline of greater than or equal to 20 mm Hg AND diastolic blood pressure less than 90 mm Hg and/or reduction from baseline of greater than or equal to 10 mm Hg . Systolic/diastolic blood pressure is based on the average of the 3 serial trough clinic sitting systolic/diastolic blood pressure measurements.</description>
          <population>Full analysis set, defined as all randomized participants who received at least 1 dose of double-blind study medication, with both a baseline value and at least 1 post-baseline value, with last observation carried forward.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="153"/>
                <count group_id="O3" value="145"/>
                <count group_id="O4" value="155"/>
                <count group_id="O5" value="151"/>
                <count group_id="O6" value="158"/>
                <count group_id="O7" value="155"/>
                <count group_id="O8" value="156"/>
                <count group_id="O9" value="155"/>
                <count group_id="O10" value="152"/>
                <count group_id="O11" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.1"/>
                    <measurement group_id="O2" value="84.3"/>
                    <measurement group_id="O3" value="84.8"/>
                    <measurement group_id="O4" value="91.0"/>
                    <measurement group_id="O5" value="82.8"/>
                    <measurement group_id="O6" value="93.0"/>
                    <measurement group_id="O7" value="45.8"/>
                    <measurement group_id="O8" value="67.9"/>
                    <measurement group_id="O9" value="39.4"/>
                    <measurement group_id="O10" value="55.3"/>
                    <measurement group_id="O11" value="62.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Treatment-emergent adverse events are adverse events that started on or after the first dose of double-blind study drug and no more than 14 days (or 30 days for a serious adverse event) after the last dose of double-blind study drug.</time_frame>
      <desc>At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Azilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QD</title>
          <description>Azilsartan medoxomil 20 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Azilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QD</title>
          <description>Azilsartan medoxomil 20 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD</title>
          <description>Azilsartan 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks.</description>
        </group>
        <group group_id="E4">
          <title>Azilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QD</title>
          <description>Azilsartan medoxomil 40 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.</description>
        </group>
        <group group_id="E5">
          <title>Azilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QD</title>
          <description>Azilsartan 80 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks.</description>
        </group>
        <group group_id="E6">
          <title>Azilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QD</title>
          <description>Azilsartan medoxomil 80 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.</description>
        </group>
        <group group_id="E7">
          <title>Chlorthalidone 12.5 mg QD</title>
          <description>Azilsartan medoxomil placebo and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks.</description>
        </group>
        <group group_id="E8">
          <title>Chlorthalidone 25 mg QD</title>
          <description>Azilsartan medoxomil placebo and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.</description>
        </group>
        <group group_id="E9">
          <title>Azilsartan Medoxomil 20 mg QD</title>
          <description>Azilsartan medoxomil 20 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks.</description>
        </group>
        <group group_id="E10">
          <title>Azilsartan Medoxomil 40 mg QD</title>
          <description>Azilsartan medoxomil 40 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks.</description>
        </group>
        <group group_id="E11">
          <title>Azilsartan Medoxomil 80 mg QD</title>
          <description>Azilsartan medoxomil 80 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="153"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Inappropriate antidiuretic hormone secretion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Inguinal hernia strangulated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Endocarditis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Uterine infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood urea increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Blood uric acid increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Heart rate increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Drop attacks</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Metabolic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Radicular syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Bipolar disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="74" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="52" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="67" subjects_at_risk="161"/>
                <counts group_id="E7" subjects_affected="51" subjects_at_risk="156"/>
                <counts group_id="E8" subjects_affected="53" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="25" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="36" subjects_at_risk="153"/>
                <counts group_id="E11" subjects_affected="32" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="161"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="156"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="7" subjects_at_risk="153"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="29" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="32" subjects_at_risk="161"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="156"/>
                <counts group_id="E8" subjects_affected="9" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="5" subjects_at_risk="153"/>
                <counts group_id="E11" subjects_affected="6" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="161"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="156"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="7" subjects_at_risk="153"/>
                <counts group_id="E11" subjects_affected="6" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Blood uric acid increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="161"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="156"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="153"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Blood urea increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="161"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="156"/>
                <counts group_id="E8" subjects_affected="19" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="161"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="156"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="161"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="156"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="19" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="19" subjects_at_risk="161"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="156"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="7" subjects_at_risk="153"/>
                <counts group_id="E11" subjects_affected="6" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="161"/>
                <counts group_id="E7" subjects_affected="19" subjects_at_risk="156"/>
                <counts group_id="E8" subjects_affected="17" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="13" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="11" subjects_at_risk="153"/>
                <counts group_id="E11" subjects_affected="12" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sr. VP, Clinical Science</name_or_title>
      <organization>Takeda Global Research and Development Center, Inc.</organization>
      <phone>800-778-2860</phone>
      <email>clinicaltrialregistry@tpna.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

